NATCO PHARMA LTD. was incorporated on 19th September, 1981
in Andhra Pradesh as a Pvt. Ltd. Company as NATCO FINE
PHARMACEUTICALS P. LTD. and became a deemed Public Company
with effect from 1st July, 1992 under Section 43A of the
Act. Subsequently, it changed its name to NATCO PHARMA
LTD. on 18th February, 1993 and received change of name
The Company began operations in 1984 with an objective to
manufacture conventional and Timed Release Dosage forms of
life savings drugs. The company's factory is located 35km.
away from Hyderabad on Bangalore Highway No. 7. to manufacture a
wide range of
tablets, capsules, liquids and dry powders using automated
Indigenisation of Microdialysis Cell technology for various
dosage forms was taken up as a challenge and Company had
introduced Antihistaminic, Antianxiety, Antiasthmatic,
Cardiac Drugs into Indian Market for the first time in
sustained action dosage forms. The major products
manufactured by the company are as follows:
FLOCY (CIPROFLOXACIN HCI),
TR PHYLLIN (THEOPHYLLINE),
BETACAP TR (PROPRANOLOL HCI),
CARDICAP TR (ISOSORBIDE-Dl-NlTRATE),
IBUBID TR (IBUPROFEN),
NACLO TR (DICLOFENAC SODIUM),
CAMRELEASE TR (DIAZEPAM),
CEPIAM TR (CHLORPHENIRAMINE MALEATE),
POTRELEASE TR (POTASSIUM CHLORIDE),
COLDACT (PHENYL PROPANOLAMINE)
HCI + CHLORPHENlRAMINE MALEATE)
The Company holds the necessary licences issued by the Drug
Control Authorities for the manufacture of these drugs at
its existing plant at Kothur, Mahaboobnagar. The turnover
of the unit increased progressively; the turnover which was
at Rs. 730 lacs for the year 1989-90 has grown to
Rs. 3689.24 Lacs for the year 1993-94.
The Company has pioneered Timed Release Technology in India
by introducing Multi-unit, Multi-layered System for the
first time in India in the year 1985. The company's
formulation Rubinat is ranked second in the Anticancer Drug
Segment and first in the Anthracyclines Segment on the
basis of turnover of 1993-94. The Company has been awarded
Import Substitution Award (1986) for Timed Release
Technology. It has well equipped Research and Development
facilities manned by qualified Scientists. Its
formulations are exported to the CIS States, Vietnam,
Hongkong, China, Netherlands, Nigeria, Tanzania and Kenya.
The Annual average exports sales for the last three years
is 21% of turnover. The Export turnover details for last
3 years are as follows:
(Rs. in lakhs)
Year Total Export % to Total
1991-92 1169.36 47.39 4%
1992-93 2840.00 739.86 26%
1993-94 3542.74 1168.64 33%
Sept. '94 3402.59 1740.15 51%
The Company is a recipient of WHO Certificate for
maintaining good manutacturing practices. The Company is
one of the contract manufacturers in the pharmaceuticals
industry in India and manufactures products for companies
including Ranbaxy Laboratories Ltd., Eskayef Ltd., Parke
Davis (I) Ltd., Fulford India Limited, Cadila Ltd., John
Wyeth India Ltd., ICI Ltd. and SOL Pharmaceuticals Ltd.
-Natco Pharma (NPL) was promoted by V C Nannapaneni an NRI based in
the US for 13 years.
-Launches the anti-migraine Sumatriptan Succinate under the brand
-Awarded an export house status by the Directorate General of Foreign
trade Ministry of Commerce
-Natco Pharma Limited have entered into an agreement giving the
former business rights for Natco's products in Russia and other CIS
-Natco Pharma (NPL) has achieved the status of the complete pharma
company on the merger of its four group companies - Natco Pharma
Natco Laboratories Natco Parenterals and Dr.Karanth Pharma Chemical
Labs - effective 1 Apr.'95.
-Natco Pharma (NPL) was promoted in 1983 by V C Nannapaneni an NRI
who had worked in the US for 13 years.
-Natco Pharma Ltd has tied up with the US pharmaceutical giant
Mallin Krodt for exporting in high volume production of naproxen.
-The Executive Director Dr. K.V. Ranga Rao has resigned but
continues in the capacity of a director.
-Entered into the formulations segment by recently introducing 34
products in the state.
-The company allotted 42,70 ,500 No. of equity shares at Rs. 17 each
on preferential basis.
-Natco Pharma has been given a revamping package from IDBI
-Dr. Mohana R Velagapudi, Dr. K V Ranga Rao and Dr. N Ramakrishna Rao
have resigned from the Board w.e.f. March 31, 2002.
-Board Approves the preferential offer of Rs 6.6 crore equity
warrants to its promoters group and Rs 6 crore 12 per cent cumulative
redeemable preference shares to FIs and banks.
-Natco Pharma Ltd, has received the approval from Therapeutic Goods
Administration (TGA), Australia for its manufacturing facility at
Mekaguda in Mehabobnagar.
-Board inducted in to the Audit Committee Dr. K U Mada as a member.
The Board constituted the Remuneration Committee with the following
members: 1) Dr. K U Mada, 2) Mr. Jahar Bhowmik, 3) Mr. R Monani, 4)
M. G S Murthy.
-Launches the anti-cancer wonder drug under the brand name VEENAT
(Imatinib 100mg capsules)
-A city pharma company has filed a criminal complaint about ‘theft’
of some of its technologies by a senior executive responsible for
technology management of its products
- launched Zoldonat Zoledronic Acid for injection. With this launch,
NATCO has become the second company to launch Zoledronic Acid in the
world, after Novartis, the patent holders.
-Launches Letronat 2.5 mg tablets (Latrozole tablets). Letrozole, the
non-sterioidal aromatase inhibitor is indicated for first-line
treatment of advanced breast cancer in postmenopausal women with
hormone receptor positive or hormone receptor unknown locally
advanced or metastatic breast cancer.
-Received an order Rs 35-fr for export of citalopram hydrobromide
(which is used for the treatment as an anti-depressant) for regulated
markets and imatinibmesylate (used for the treatmemt of chronic
-Following shareholders have sold shares in the company: 1) VC
Nannapaneni - 90,000 shares, 2) Time Cap Pharma Labs Pvt. Ltd. -
-Received a letter from Mr. V. C. Nannapaneni, one of the share
holders informing the Company that he has sold 3,32,554 shares and
that his post sale holding is 49,65,346 shares (28.57% of the paid up
- An award has being presented titled as DSIR National Award for R&D
efforts in the Industry (2003) under the Dept. of Scientific and
Industrial Research, Ministry of Science and Technology, Govt. of
- Mr Rajeev Nannapaneni has been appointed as new Chief Operating
Officer of the Company w.e.f December 1, 2003.
-Promoters offload shares to raise funds
-Unveils new drug for brain tumour therapy, Temozolomide under the
brand name `Temonat' indicated for treatment of certain forms of
-Launches Geftinib 250 mg., an anti-cancer drug, under the brand name
-Natco Pharma Limited has informed that the sad and sudden demise of
Mr. Raj Monani, one of the Company's Board of Directors
-Natco Pharma Ltd has informed the that the company has launched
Ganciclovir in 250 mg. capsules and 500 ml injection forms
-Natco Launches anti Cancer Drug, establishes Oncology division
-Natco Pharma Ltd, the Hyderabad-based pharmaceutical company known
for its timed-release technology and affordable drugs in cancer
therapy, has bagged the award from the Indian Red Cross Society of
-NATCO launches drug to treat prostate cancer
-NATCO launches drug for Ovarian Cancer
-Launches Curcumin 500 mg capsules under the brand name Turcumin
- Receives Certification of Suitability of Monographs of the European
Pharmacopoeia for its active pharmaceutical ingredients - Ondansetron
Hydrochloride Dihydrate and Sumatriptan Succinate by European
Directorate for the Quantity of Medicines (EDQM).
-Natco Pharma Limited signs memorandum of understanding (MoU) for
sharing technology related to manufacture of oncology products.
-Natco Pharma launches anti-migraine drug
-Natco Pharma ties up with Temple University, USA
-Natco Pharma launches Vorizol
-Natco announces launch of Pemnat (Pemetrexed) for treatment of
non-small cell lung cancer
-Natco Pharma Ltd has announced the launch of a world class oral
contraceptive under the brand name Tarana.
- Natco Pharma Ltd ties up with Dr. Reddy's for oncological
-Natco Pharma - Natco launches BENDIT(Bendamustine).
-Natco Pharma - NATCO launches Anastrazole in the USA.
-NATCO's new chemical entity (NCE) receives 'Orphan' designation
from, US FDA.
-Natco files ANDA for generic Tykerb, Ties up with Lupin Limited.
-NATCO and Levomed LLC, USA formed a Joint Venture company,
NATCOFARMA DO BRASIL for sales and distribution in Brazil.
-Golden Peacock Award for Corporate Social Responsibility - 2012.
-NATCO Pharma receives approval for Lansoprazole capsules.
-Natco Pharma gets marketing approval for Rizatriptan Benzoate
tablets orally disintegrating 5 mg and 10 mg. Used for the treatment
of migraine headaches with or without aura.
-Natco Pharma hits 52-week high on getting US Court nod for generic
Copaxone used for treating multiple sclerosis.
-Natco Pharma zooms over 11% on winning cancer drug case
-Natco's Kothur Formulation Facility found acceptable by USFDA.
-Natco Pharma gets USFDA nod for Oseltamivir Phosphate Capsules.
- Natco Pharma announced that it's marketing partner in the USA,
Breckenridge Pharmaceuticals, Inc. (BPI), has filed an Abbreviated
New Drug Application (ANDA) for its Everolimus 0.25 mg, 0.5 mg and
0.75 mg tablets.
-Natco launches HEPCINAT LP in Nepal
-Natco received the Best Speciality Brand-SILVER AWARD” for marketing
excellence in India
-Natco Pharma Limited, Winner Of ‘ Golden Peacock Innovation
Management Award’ For The Year 2015
-Natco launches HEPCINAT in Nepal- 1 st generic version of Sofosbuvir
(Sovaldi®) in the country
-Natco Pharma has splits its face value from Rs. 10 to Rs. 2